Abstract
111In-BLEDTA is a bleomycin-containing radiopharmaceutical that has proven useful as a tumor imaging agent. Whole blood distribution and pharmacokinetic parameters were studied in nine cancer patients, and the results compared with previously reported studies using 57Co-bleomycin. In eight patients studied by bolus intravenous injection, 111In-BLEDTA had a beta half-life (t( 1/2 β)) of 1.3 hours, a terminal-phase half-life (t( 1/2 )) of 11.7 hours, a volume of distribution (V(dγ)) of 57.5 L/m2, a total body clearance rate (C(1b2)) of 52.8 ml/min/m2, a renal clearance rate (C1(r)) of 23.3 ml/min/m2, and a 24-hour urinary excretion of 38.1% total administered dose. 111In-BLEDTA and 57Co-bleomycin have similar C1(bs) but differing V(ds). Polymorphonuclear cell uptake of 111In-BLEDTA may explain its shorter t( 1/2 β) and t( 1/2 ), as well as its lower C1(r) and 24-hour urinary excretion. While the biologic characteristics of 111In-BLEDTA contribute to a greater background activity than is observed in scans with 57Co-bleomycin, its superior physical properties render it clinically more desirable as a tumor-imaging radiopharmaceutical.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 221-227 |
| Number of pages | 7 |
| Journal | Investigative Radiology |
| Volume | 19 |
| Issue number | 3 |
| State | Published - 1984 |
Fingerprint
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Radiological and Ultrasound Technology
Cite this
Pharmacokinetics of indium-111 BLEDTA in man. / Sartoris, D. J.; Goodwin, D. A.; Meares, C. F.; DeRiemer, L. H.; Fajardo, L. F.
In: Investigative Radiology, Vol. 19, No. 3, 1984, p. 221-227.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacokinetics of indium-111 BLEDTA in man
AU - Sartoris, D. J.
AU - Goodwin, D. A.
AU - Meares, C. F.
AU - DeRiemer, L. H.
AU - Fajardo, L. F.
PY - 1984
Y1 - 1984
N2 - 111In-BLEDTA is a bleomycin-containing radiopharmaceutical that has proven useful as a tumor imaging agent. Whole blood distribution and pharmacokinetic parameters were studied in nine cancer patients, and the results compared with previously reported studies using 57Co-bleomycin. In eight patients studied by bolus intravenous injection, 111In-BLEDTA had a beta half-life (t( 1/2 β)) of 1.3 hours, a terminal-phase half-life (t( 1/2 )) of 11.7 hours, a volume of distribution (V(dγ)) of 57.5 L/m2, a total body clearance rate (C(1b2)) of 52.8 ml/min/m2, a renal clearance rate (C1(r)) of 23.3 ml/min/m2, and a 24-hour urinary excretion of 38.1% total administered dose. 111In-BLEDTA and 57Co-bleomycin have similar C1(bs) but differing V(ds). Polymorphonuclear cell uptake of 111In-BLEDTA may explain its shorter t( 1/2 β) and t( 1/2 ), as well as its lower C1(r) and 24-hour urinary excretion. While the biologic characteristics of 111In-BLEDTA contribute to a greater background activity than is observed in scans with 57Co-bleomycin, its superior physical properties render it clinically more desirable as a tumor-imaging radiopharmaceutical.
AB - 111In-BLEDTA is a bleomycin-containing radiopharmaceutical that has proven useful as a tumor imaging agent. Whole blood distribution and pharmacokinetic parameters were studied in nine cancer patients, and the results compared with previously reported studies using 57Co-bleomycin. In eight patients studied by bolus intravenous injection, 111In-BLEDTA had a beta half-life (t( 1/2 β)) of 1.3 hours, a terminal-phase half-life (t( 1/2 )) of 11.7 hours, a volume of distribution (V(dγ)) of 57.5 L/m2, a total body clearance rate (C(1b2)) of 52.8 ml/min/m2, a renal clearance rate (C1(r)) of 23.3 ml/min/m2, and a 24-hour urinary excretion of 38.1% total administered dose. 111In-BLEDTA and 57Co-bleomycin have similar C1(bs) but differing V(ds). Polymorphonuclear cell uptake of 111In-BLEDTA may explain its shorter t( 1/2 β) and t( 1/2 ), as well as its lower C1(r) and 24-hour urinary excretion. While the biologic characteristics of 111In-BLEDTA contribute to a greater background activity than is observed in scans with 57Co-bleomycin, its superior physical properties render it clinically more desirable as a tumor-imaging radiopharmaceutical.
UR - http://www.scopus.com/inward/record.url?scp=0021277167&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021277167&partnerID=8YFLogxK
M3 - Article
C2 - 6206021
AN - SCOPUS:0021277167
VL - 19
SP - 221
EP - 227
JO - Investigative Radiology
JF - Investigative Radiology
SN - 0020-9996
IS - 3
ER -